BLRX - BioLineRx Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.6550
-0.0168 (-2.50%)
At close: 3:51PM EST

0.6450 -0.01 (-1.53%)
Pre-Market: 7:02AM EST

Stock chart is not supported by your current browser
Previous Close0.6718
Open0.6601
Bid0.6450 x 6400
Ask0.6950 x 11700
Day's Range0.6450 - 0.6800
52 Week Range0.6400 - 1.8400
Volume180,362
Avg. Volume1,333,961
Market Cap79.453M
Beta (3Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.2320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 11, 2018 at the Convene Conference Center near Grand Central Terminal in New York, N.Y. BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4 in late clinical development for the treatment of solid tumors, acute myeloid leukemia (AML) and stem-cell mobilization for bone-marrow transplantation.

  • ACCESSWIRE20 days ago

    New Healthcare Trends Have Investors Looking at 4 Stocks

    Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.

  • PR Newswire20 days ago

    BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134

    TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Food and Drug Administration (FDA) has granted the Biological Product Designation for AGI-134, the Company's novel immunotherapy compound. This designation provides the Company with eligibility to obtain 12 years of market exclusivity upon approval of the product for commercial use by the FDA.

  • GlobeNewswire24 days ago

    Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswirelast month

    BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update

    Management to hold conference call at 10:00 am EST TEL AVIV, Israel , Nov. 8, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology ...

  • PR Newswirelast month

    BioLineRx to Report Third Quarter 2018 Results on November 8, 2018

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended September 30, 2018 on Thursday, November 8, 2018, before the US markets open. The Company will host a conference call on Thursday, November 8, 2018 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire2 months ago

    BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

    BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today disclosed additional data from the in-depth analyses of biopsies of the dual combination arm of the Phase 2a COMBAT/KEYNOTE-202 study, evaluating patients with metastatic pancreatic adenocarcinoma (PDAC) treated with BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside of the United States and Canada). The results presented today at a poster discussion session at the European Society for Medical Oncology 2018 Congress, in Munich, Germany, demonstrate that BL-8040 significantly improves T-cell infiltration into the tumor and reduces immunosuppression in the tumor microenvironment.

  • PR Newswire2 months ago

    BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

    BL-8040 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer Encouraging results support further development ...

  • ACCESSWIRE2 months ago

    BioLineRx, High Potential Near Term Catalysts, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on BioLineRx Ltd. (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds develop them through pre-clinical and/or clinical stages, then partners with pharmaceutical companies for advanced clinical development and/or commercialization. The company' shares continue to gain possibly driven by the impact of its recent announcements.

  • Can The Uptrend Continue for BioLineRx (BLRX)?
    Zacks2 months ago

    Can The Uptrend Continue for BioLineRx (BLRX)?

    Investors certainly have to be happy with BioLineRx Ltd. (BLRX) and its short term performance.

  • BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher
    Zacks2 months ago

    BioLineRx (BLRX) in Focus: Stock Moves 7.5% Higher

    BioLineRx (BLRX) shares rose nearly 8% in the last trading session, amid huge volumes.

  • BioLineRx Stock Up on Stake Increase in Lead Cancer Program
    Zacks2 months ago

    BioLineRx Stock Up on Stake Increase in Lead Cancer Program

    BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: BioLineRx and OPKO Health

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...

  • PR Newswire2 months ago

    BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications

    TEL AVIV, Israel, Oct. 3, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that it has entered into an agreement with Biokine Therapeutics to increase BioLineRx's stake in its lead oncology platform, BL-8040, a CXCR4 antagonist currently in late stage clinical development in both solid tumor and hematological indications, including stem cell mobilization (SCM), acute myeloid leukemia (AML) and immunotherapy for multiple types of solid tumors. As a result of the transaction, BioLineRx will increase its economic stake in the program to 80% from the previous level of 60%.

  • Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status
    Zacks2 months ago

    Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status

    Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.

  • BioLineRx (BLRX) Continue to Surge Higher?
    Zacks3 months ago

    BioLineRx (BLRX) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in BioLineRx Ltd. (BLRX).

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and BioLineRx

    NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Wall Street closed up on Thursday as upbeat economic data and strong corporate earnings helped buoy equities. Unemployment dropped by 3000 to a seasonally ...

  • PR Newswire3 months ago

    BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, will present a company update at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis Hotel in New York City. The BioLineRx presentation is scheduled to start at 9:35 a.m. EDT on Wednesday, September 5, 2018. A live audio webcast of the presentation will be available online on the Investor Page of the Company's website.

  • ACCESSWIRE4 months ago

    Bioline RX Ltd Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2018 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 13, 2018 at 10:00 AM ...

  • PR Newswire4 months ago

    BioLineRx Reports Second Quarter 2018 Financial Results

    TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...

  • PR Newswire4 months ago

    BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF), to G-CSF alone, for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients. The open-label, single-arm, lead-in period of the study was designed to include up to 30 patients, with Data Monitoring Committee (DMC) review after completion of approximately 10, 20 and 30 patients, in order to assess safety and efficacy following treatment with BL-8040 plus G-CSF.

  • PR Newswire4 months ago

    BioLineRx to Report Second Quarter 2018 Results on August 13, 2018

    TEL AVIV, Israel, Aug. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended June 30, 2018 on Monday, August 13, 2018, before the US markets open. The Company will host a conference call on Monday, August 13, 2018 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.

  • PR Newswire4 months ago

    BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

    BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, universally applicable, multi-arm mechanism that targets patient-specific tumor neoantigens. AGI-134 is a synthetic, intratumorally administered glycolipid designed to label cancer cells with alpha-Gal, which then become the target of pre-existing anti-Gal antibodies, effectively triggering an immediate local anti-tumor response, as well as a follow-on systemic anti-tumor response targeting both the primary injected tumor and distal secondary tumors. The study is primarily designed to evaluate the safety and tolerability of AGI-134, given both as monotherapy and in combination with an immune checkpoint inhibitor, in unresectable metastatic solid tumors.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Social Reality Inc (NASDAQ: SRAX ) stock was trading ...

  • PR Newswire4 months ago

    BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer

    TEL AVIV, Israel, July 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) for the support of a Phase 2a program investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA, in patients with metastatic pancreatic cancer. Under the expansion, a triple combination arm investigating the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy will be added to the ongoing COMBAT/KEYNOTE-202 study.